JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

METTL3/MALAT1/ELAVL1 Axis Promotes Tumor Growth in Ovarian Cancer

  • 0Department of Obstetrics and Gynecology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, Guangdong, People's Republic of China.
Oncotargets and Therapy +

|

February 13, 2024

|

February 13, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

The METTL3 enzyme promotes ovarian cancer (OC) by enhancing the stability of MALAT1 mRNA through N6-methyladenosine modification. This interaction, involving ELAVL1, highlights METTL3 as a potential therapeutic target in OC.

Area Of Science

  • Oncology
  • Molecular Biology
  • Epigenetics

Background

  • N6-methyladenosine (m6A) modification is increasingly implicated in cancer development.
  • The precise role of METTL3, a key m6A methyltransferase subunit, in ovarian cancer (OC) remains largely undefined.

Purpose Of The Study

  • To investigate the regulatory mechanisms of METTL3 in ovarian cancer.
  • To elucidate the role of METTL3 and MALAT1 in OC progression.

Main Methods

  • Utilized the GEPIA 2.0 database for expression and survival analyses of OC.
  • Conducted in vitro and in vivo experiments to explore METTL3's regulatory functions in OC.
  • Performed knockdown assays for METTL3 and MALAT1 to assess their impact on OC cell proliferation.

Main Results

  • METTL3 and MALAT1 were significantly overexpressed in OC tissues and cells.
  • Knocking down METTL3 or MALAT1 reduced OC cell proliferation.
  • METTL3 enhances MALAT1 stability via m6A modification, with ELAVL1 upregulating MALAT1 expression.

Conclusions

  • METTL3 acts as an oncogenic molecule promoting ovarian cancer occurrence.
  • METTL3's carcinogenic effect is mediated by enhancing MALAT1 mRNA stability through m6A modification, involving the RNA-binding protein ELAVL1.

Keywords:

Related Concept Videos

Tumor Progression 02:07

6.3K

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

mTOR Signaling and Cancer Progression 03:03

3.8K

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Metastasis 02:30

5.5K

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

The Tumor Microenvironment 02:17

6.6K

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

PI3K/mTOR/AKT Signaling Pathway 01:22

3.6K

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...

Cancer Cell Migration through Invadopodia 01:35

2.3K

Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...